用二酶2A和4B的基因疗法通过改善亚细胞cAMP细分来改善心力衰竭和心律失常
Nikoleta Pavlaki1,2, Alexander Froese1,2, Wener Li3
1Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany.
Cardiovascular research
|May 22, 2024
概括
使用固酶 (PDEs) 的基因疗法通过恢复特定细胞区的循环腺单 (cAMP) 信号传递来预防心力衰竭 (HF). 这种方法可以改善心脏功能并减少心律失常.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 基因治疗 基因治疗
背景情况:
- 心脏固酶 (PDEs) 调节循环腺单酸盐 (cAMP) 水平,这对心脏功能至关重要.
- 以前的研究表明,PDE基因疗法可以预防心力衰竭 (HF),但机制尚不清楚.
- 在亚细胞微域中改变的cAMP分区与HF病变产生有关.
研究的目的:
- 调查PDE2A和PDE4B基因疗法是否可以预防小鼠的压力过载诱导的HF.
- 阐明在不同的亚细胞微域中恢复cAMP细分的作用.
- 评估对心脏重塑和心律失常的影响.
主要方法:
- 在小鼠中通过横向大动脉收缩诱导HF.
- 9型腺相关病毒的PDE2A3,PDE4B3或光酶的载体介导过度表达.
- 使用心声学和组织学评估心脏形态和功能的评估.
- 使用cAMP生物传感器对活细胞进行成像,以分析cAMP细分.
- 单细胞和人类诱导的多能干干衍生的心肌细胞的电生理学研究.
主要成果:
- PDE2A和PDE4B基因治疗减弱了心脏缩,纤维化和收缩功能障碍.
- 在RyR2和caveolae微域中,PDE过度表达恢复了cAMP分区.
- 观察到心脏重塑标记的改善和心律失常的减少.
- 在疾病模型中,PDE4B与RyR2有很强的关联,可以防止泄漏.
结论:
- 使用PDEs的基因疗法有效地防止HF和相关的心脏重塑.
- 恢复亚细胞微域中的cAMP细分是关键机制.
- 这种方法有可能用于治疗HF和预防心律失常.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157